Positive results from first phase 3 trial with N8-GP, a long-acting factor VIII for treatment of haemophilia A

Bagsværd, Denmark, 19 March 2014 - Novo Nordisk today announced the completion of pathfinder(TM)2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. Pathfinder(TM)2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment in patients with haemophilia A, who are 12 years or older. For further information Media: Katrine Sperling +45 3079 6718 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Frank Daniel Mersebach +45 3079 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 16 / 2014

The release as fetched from its publisher. novonordisk.com ↗